Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. (Full PDF)
1. C Rolf,
2. B Engström,
3. C Beauchard,
4. L D Jacobs and
5. A Le Liboux
+ Author Affiliations
- 1. Department of Orthopaedic Surgery, Huddinge University Hospital, Sweden.
Abstract
OBJECTIVE: The primary objective of this study was to assess the kinetics of ketoprofen in synovial fluid and intra-articular tissues in relation to plasma. The secondary objective was to study whether intra-articular tissues act as reservoirs.
METHODS: The ketoprofen concentration was analysed in plasma, synovial fluid and intra-articular tissues after single application of a 30 mg plaster (n = 40), multiple applications for 5 days (n = 30) or oral intake of 50 mg (n = 30) in patients undergoing knee arthroscopy.
RESULTS: Median CMax values after topical application were 12.8 ng/ml in synovial fluid, 56.7 ng/g in synovial tissue, 349.3 ng/g in meniscus and 568.9 ng/g in cartilage.
CONCLUSION: Topical applications of ketoprofen allow the attainment of high intra-articular tissue concentrations.
Topical Ketoprofen Patch (100 mg) for the Treatment of Ankle Sprain: A Randomized, Double-Blind, Placebo-Controlled Study
- Bernard Mazières, MD*,†,
- Stéphanie Rouanet, DESS‡,
- Joanne Velicy, PhD‡,
- Claudia Scarsi, PharM§, and
- Valentina Reiner, PharB§
+Author Affiliations
- Address correspondence to Bernard Mazières, MD, Department of Rheumatology, Rangueil University Hospital, 1, Avenue Jean-Poulhes, 31059–Toulouse Cedex 9, France (e-mail: mazieres@cict.fr).
Abstract
Background: Topical nonsteroidal anti-inflammatory drugs offer the advantage of enhanced drug delivery to local affected tissues with low plasma levels and an expected reduced incidence of systemic adverse events (mainly peptic ulcer disease and gastrointestinal hemorrhage).
Hypothesis: To test the efficacy and tolerability of a 100-mg patch of ketoprofen applied once a day.
Study Design: Randomized controlled clinical trial; Level of evidence, 1.
Methods: The 2-week trial included patients suffering painful (spontaneous pain ≥50 mm on a 0- to 100-mm visual analog scale), benign (grade I or II), recent (<2 days=”” ankle=”” sprains=”” as=”” a=”” model=”” of=”” general=”” traumatic=”” soft=”” tissue=”” injuries=”” the=”” primary=”” efficacy=”” criterion=”” was=”” spontaneous=”” pain=”” change=”” after=”” 7=”” treatment=”” in=”” intention-to-treat=”” population=”” one=”” hundred=”” sixty-three=”” patients=”” were=”” randomized=”” ketoprofen=”” 81=”” placebo=”” 82=”” span=””>
Results: After 1 week of treatment, the decrease in spontaneous pain was −50 ± 20 mm for ketoprofen and −38 ± 24 mm for the placebo, showing a statistically significant intergroup difference (P = .0007). The majority of the secondary criteria were also statistically significant in favor of the ketoprofen patch. Tolerance was good in both groups, adverse events being mostly local.
Conclusion: This trial suggested that a 7-day course of treatment with a ketoprofen patch is useful in benign ankle sprain, without revealing unexpected adverse events.
Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management: Review (full PDF)
+Author Affiliations
Pain and Anaesthesia Research Centre, Boyle’s Department of Anaesthesia & Pain Medicine, St Bartholomew’s Hospital, London, UK
- Correspondence toDr Vivek Mehta, Pain and Anaesthesia Research Centre, Boyle’s Department of Anaesthesia & Pain Medicine, St Bartholomew’s Hospital, London EC1A 7BE, UK; vivek.mehta@mac.com
- Received 5 July 2011
- Accepted 8 October 2011
- Published Online First 3 November 2011
Abstract
Chronic pain can lead to significant disability with social and economic implications in the community. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) have been part of the management of chronic pain. The risk of adverse events with traditional NSAIDs has led to the development of alternative therapeutic options. Differential blockade of the enzymes involved in pain and inflammation can offer therapeutic options without the gastrointestinal side effects. However, this may be at the expense of other major cardiovascular side effects. Pain pathways that involve peripheral transmission may be altered by local application of analgesia to the skin overlying the painful area. Recent guidelines for osteoarthritis treatment from the National Institute for Health and Clinical Excellence highlight the importance of topical NSAIDs in the armamentarium of pain management. NSAID combination drugs with gastric protection have provided alternatives to traditional NSAIDs, but the long term sequelae are unknown.
Drugs Used in Transdermal Pain
Back to Physicians Page
Back to Ingredients Page